Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.71 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SCN1A | P35498 | 1/20 | 0.35 |
| ▸ | SCN4A | P35499 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.35 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11896944 | 0.83 | SCN8A (0.53) | CYP1A2SCN8ACYP2D6ALDH1A1SCN1A | |
| SCHEMBL13583942 | 0.81 | SCN8A (0.52) | CYP1A2SCN8ACYP2D6ALDH1A1SCN1A | |
| SCHEMBL1768502 | 0.80 | CYP1A2 (0.48) | CYP1A2SCN8ACYP2D6ALDH1A1SCN1A | |
| SCHEMBL12649290 | 0.78 | CYP1A2 (0.53) | CYP1A2SCN8ACYP2D6ALDH1A1SCN1A | |
| SCHEMBL11896945 | 0.77 | CYP1A2 (0.45) | CYP1A2SCN8ACYP2D6ALDH1A1 | |
| SCHEMBL11896968 | 0.75 | CYP1A2 (0.65) | CYP1A2SCN8ACYP2D6CYP3A4ALDH1A1 | |
| SCHEMBL1768554 | 0.75 | CYP2D6 (0.68) | CYP1A2SCN8ACYP2D6CYP3A4SCN1A | |
| Ammonia Solution, Strong SCHEMBL1768336 | 0.74 | CYP1A2 (0.64) | CYP1A2SCN8ACYP2D6CYP3A4ALDH1A1 | |
| SCHEMBL1768500 | 0.73 | CYP1A2 (0.41) | CYP1A2SCN8ACYP2D6ALDH1A1SCN1A | |
| SCHEMBL1899225 | 0.63 | CYP2D6 (1.00) | CYP1A2SCN8ACYP2D6CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283295-A1 | INDAZOLE DERIVATIVES AND THEIR USE FOR BLOCKADING VOLTAGE DEPENDENT SODIUM CHANNELS | UNIVERSITY COLLEGE LONDON (GB) | 2012-11-08 | — | — | US | disclosed |
| US-20120283295-A1 | INDAZOLE DERIVATIVES AND THEIR USE FOR BLOCKADING VOLTAGE DEPENDENT SODIUM CHANNELS | UNIVERSITY COLLEGE LONDON (GB) | 2012-11-08 | — | — | US | disclosed |
| US-20120283295-A1 | INDAZOLE DERIVATIVES AND THEIR USE FOR BLOCKADING VOLTAGE DEPENDENT SODIUM CHANNELS | UNIVERSITY COLLEGE LONDON (GB) | 2012-11-08 | — | — | US | disclosed |
| EP-2483270-A1 | INDAZOLE DERIVATIVES AND THEIR USE FOR BLOCKADING VOLTAGE DEPENDENT SODIUM CHANNELS | University College London (GB) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011061469-A1 | INDAZOLE DERIVATIVES AND THEIR USE FOR BLOCKADING VOLTAGE DEPENDENT SODIUM CHANNELS | UNIVERSITY COLLEGE LONDON (GB) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283295-A1 | INDAZOLE DERIVATIVES AND THEIR USE FOR BLOCKADING VOLTAGE DEPENDENT SODIUM CHANNELS | SCN3A, CACNB3, CACNA1B | CYP1A2 874/4885SCN8A 103/4885CYP2D6 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.